A detailed history of Mariner, LLC transactions in Geron Corp stock. As of the latest transaction made, Mariner, LLC holds 34,879 shares of GERN stock, worth $131,493. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,879
Previous 43,344 19.53%
Holding current value
$131,493
Previous $183,000 13.66%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.17 - $4.99 $35,299 - $42,240
-8,465 Reduced 19.53%
34,879 $158,000
Q2 2024

Aug 13, 2024

BUY
$3.1 - $5.09 $32,137 - $52,768
10,367 Added 31.44%
43,344 $183,000
Q1 2024

May 15, 2024

BUY
$1.75 - $3.44 $28,540 - $56,102
16,309 Added 97.85%
32,977 $108,000
Q4 2023

Feb 14, 2024

SELL
$1.74 - $2.31 $1,179 - $1,566
-678 Reduced 3.91%
16,668 $35,000
Q3 2023

Nov 13, 2023

BUY
$2.11 - $3.28 $844 - $1,312
400 Added 2.36%
17,346 $36,000
Q2 2023

Aug 11, 2023

BUY
$1.97 - $3.69 $1,784 - $3,343
906 Added 5.65%
16,946 $54,000
Q1 2023

May 12, 2023

BUY
$2.14 - $3.4 $960 - $1,526
449 Added 2.88%
16,040 $35,000
Q4 2022

Feb 14, 2023

BUY
$2.03 - $2.42 $111 - $133
55 Added 0.35%
15,591 $38,000
Q3 2022

Nov 10, 2022

BUY
$1.67 - $2.94 $25,945 - $45,675
15,536 New
15,536 $36,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.42B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.